PSTV News and Press, PLUS THERAPEUTICS Inc. From 10/31/23

New survival data from 15 patients in the Phase 2 ReSPECT-GBM trial of rhenium ( 186 Re) obisbemeda in recurrent glioblastoma (rGBM) will be presented at SNO Annual Meeting on November 17 th ; Company will also host a Key Opinion Leader (KOL) event following the meeting to...

Tennant Company (TNC) is expected to report for Q3 2023 Stellantis N.V. (STLA) is expected to report for Q3 2023 Marathon Petroleum Corporation (MPC) is expected to report $7.79 for Q3 2023 Easterly Government Properties Inc. (DEA) is expected to report $0.29 for Q3 2023 Allegion ...

2023-10-30 17:35:37 ET Major earnings expected after the bell on Tuesday include: Advanced Micro Devices ( AMD ) Amgen ( AMZN ) Lumen Technologies ( LUMN ) Chesapeake Energy Corporation ( CHK ) First Solar ( FSLR ) For further details see: ...

AUSTIN, Texas, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today annou...

AUSTIN, Texas, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today annou...

Blackstone Inc. (BX) is expected to report $0.99 for Q3 2023 S&T Bancorp Inc. (STBA) is expected to report $0.9 for Q3 2023 Watsco Inc. Class B (WSO.B) is expected to report for Q1 2024 Alaska Air Group Inc. (ALK) is expected to report $1.88 for Q3 2023 Metropolitan Bank Holdi...

PLUS THERAPEUTICS Inc. (PSTV) is expected to report $-0.58 for Q3 2023

Cohort 4 of the ReSPECT-LM Phase 1 dose escalation trial is the first of 4 planned cohorts in Part B; the Company anticipates moving into Cohort 5 following standard safety review Updates on the ReSPECT-LM trial and on the ReSPECT-GBM trials in recurrent glioblastoma are planned for Novem...

AUSTIN, Texas, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced th...

2023-09-13 10:00:09 ET More on Health Care Select Sector SPDR Seeking Alpha’s Quant Rating on Health Care Select Sector SPDR Dividend scorecard for Health Care Select Sector SPDR Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare ( XLV ) ...